-
Drug List:
- Recombinant Proteins:
- -- Etanercept
- Monoclonal antibodies:
- -- Trastuzumab
- -- Rituximab
- -- Abciximab
- -- Bevacizumab
- Immunotoxins:
- -- Denileukin Difitox
- Radionuclide Conjugates:
- -- Ibritumomab Tiuxetan
- -- Bapromab penditide
- -- imciromab penetate
- Antisense oligonucleotides:
- --fomiversin
- --pegaptinib
-
Etanercept (recombinant protein)
- MOA:
- Binds to TNF-anti inflammatory
- Coverage:
- Treatment for arthritis, break cycle of inflammation by binding TNF.
- Acts as a decoy
-
Trastuzumab (monoclonal antibody)
- MOA:
- Herceptin-, anti epidermal growth factor receptor 2
- - Prevents receptor activation
- Coverage:
- Slows breast tumor growth
-
Bevacizumab (Monoclonal antibody)
- MOA:
- Blocks VEGF and slows tumor growth
-
Rituximab (monoclonal antibody)
- MOA:
- Clears B cells by targetting CD20 antigen
- Coverage:
- Treat non-Hodgkin B cell lymphoma (NHL). Also approved for rheumatoid arthritis, supressing B cell function and
- the production of Ab against proteins usually found in the joints
-
Abciximab (monoclonal antibody)
- MOA:
- Minimizes platelet thrombosis and artery re-stenosis
-
Denileukin-difitox (immunotoxin)
- MOA:
- Recombinant fusion of protein IL-2 (targeting) and toxin domain from diphtheria.
- -- targets ribosomes
- Coverage:
- Treats T cell lymphomas expressing IL-2 receptors
- -- Replenish T cell from marrow after T cell depletion
-
Ibritumomab tiuxetan (radionuclide conjugate)
-- short half life, beta emitter.
- MOA:
- 131I or 90Yt is antiCD20 conjugated with 90Yt
- Coverage:
- Low grade lymphoma
- follifular lymphoma
- transformed NHL (relapsed or refractory)
-
Capromab penditide (radionuclide conjugate)
-- short half life, beta emitters
- MOA:
- 111In used for nuclear imaging
- Coverage:
- Prostate tumor specific antibody.
- Detect metastases
-
Imciromab pentetate (radionuclide conjugate)
-- short half life, beta emitter
- MOA:
- 111In for nuclear imaging
- Coverage:
- Detects cardiac actin: reveals sites of myocardial tissue damage
-
Fomiversin (antisense oligonucleotide)
- MOA:
- Phosphorothioate oligonucleotide against IE2 gene of cytomegalovirus
- -- blocks CMV replication
- Coverage:
- Treat CMV retinitis in AIDS patients
- administered intraocularly to achieve high concentrations (DNA)
-
Pegaptinib (antisense oligonucleotide)
- MOA:Directed against VEGF (blocks neovascularization)
- Coverage:Wet macular degeneration
|
|
